Listap 150 SR Tablet contains Epalrestat 150 mg as its active ingredient and is primarily indicated for the management of diabetic neuropathy. Epalrestat is an aldose reductase inhibitor that acts by preventing the conversion of glucose to sorbitol, thereby reducing intracellular sorbitol accumulation in peripheral nerves, which is implicated in the pathogenesis of diabetic neuropathy. By inhibiting aldose reductase, Listap 150 SR helps to alleviate symptoms such as numbness, burning sensation, and pain associated with nerve damage in diabetic patients. The sustained-release formulation ensures a steady plasma concentration of Epalrestat, enhancing therapeutic efficacy and improving patient compliance through once-daily dosing. It is generally well-tolerated, with adverse effects being mild and infrequent, including gastrointestinal discomfort and skin rash. Listap 150 SR should be used under medical supervision, especially in patients with hepatic or renal impairment, and is contraindicated in individuals with hypersensitivity to Epalrestat or its excipients. Regular monitoring of liver function tests is recommended during prolonged therapy. This medication is an adjunct to optimal glycemic control and lifestyle modifications in the comprehensive management of diabetic neuropathy, aiming to improve quality of life and prevent progression of nerve damage.